Skip to main content
. 2023 Feb 24;23(6):2867–2875. doi: 10.1007/s10238-023-01024-1

Table 2.

Clinical features of MTX responders and MTX non-responders

MTX
responders
(N = 4)
MTX
non-responders
(N = 4)
DAS28 at baseline (median [range]) 5.1 [4.3–6.7] 4.4 [4.2–5.1]
DAS28 post MTX treatment (median [range]) 2.7 [2.1–3.1] 4.5 [4.1–5.2]
ΔDAS28 (median [range]) 2.5 [1.5–4.2] -0.01 [-0.2–0.1]
ACPA positive [in %] 4 [100] 4 [100]
RF positive [in %] 3 [75] 3 [75]
Former smokers [in %] 4 [100] 4 [100]